PTO/SB/088 (02-03)

Approved for use through 04/30/2003, OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known **Application Number** 10/651,828 Filing Date INFORMATION DISCLOSURE 08/28/2003 STATEMENT BY APPLICANT First Named Inventor ZOLOTUKHIN **Art Unit** 1633 /636 (Use as many sheets as necessary) Examiner Name DAVID GUZ0 Sheet **Attorney Docket Number** 5853-251

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
92		Wu et al. Adeno-Associated Virus Vector-Mediated Transgene Integration into Neurons and Other Nondiving Cell Targets. Journal of Virology. July 1998, Vol. 72, No. 7, pages 5919-5926.	
81	•	Wu et al. Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism. Journal of Virology. September 2000, Vol. 74, No. 18, pages 8635-8647.	
or		Grifman et al. Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids. Molecular Therapy. June 2001, Vol. 3, pages 964-975.	
01		Girod et al. Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type-2. Nature Medicine. September 1999, Vol. 5, pages 1052-1056.	
01		Xie et al. The Atomic Structure of Adeno-Associated Virus (AAV-2), A Vector for Human Gene Therapy. Proceedings of the National Academy of Sciences. August 2002, Vol. 99, No. 16, pages 10405-10410.	
27		Rabinowitz et al. Building a Better Vector: The Manipulation of AAV Virions. Virology. 2000, Vol. 278, pages :301-308.	
d		Monahan et al. AAV Vectors: Is Clinical Success on the Horizon? Gene Therapy. 2000, Vol. 7, pages 24-30.	
91		He et al., A Simplified System for Generating Recombinant Adenoviruses. Proceedings of the National Academy of Sciences. March 1998, Vol. 95, pages 2509-2514.	
ge		Xiao et al. Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus. Journal of Virology. March 1998, Vol. 72, No. 3, pages 2224-2232.	
02		Davidson et al. Recombinant Adeno-Associated Virus Type 2, 4 and 5 Vectors: Transduction of Variant Cell Types and Regions in the Mammalian Central Nervous System. Proceedings of the National Academy of Sciences. Vol. 97, No. 7, pages 3428-3432.	-

Examiner Signature	David Junos	Date Considered	11/16/05
3.3.3.3	200-00 7 0 - 10	Constacted	/

^{*}EXAMINER: Initial if reference considered, whether or post lation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: